Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
Nurix Therapeutics Inc (NASDAQ: NRIX) closed the day trading at $8.33 down -4.25% from the previous closing price of $8.7. In other words, the price has decreased by -$4.25 from its previous closing price. On the day, 1.15 million shares were traded. NRIX stock price reached its highest trading level at $8.605 during the session, while it also had its lowest trading level at $8.215.
Ratios:
For a better understanding of NRIX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.82 and its Current Ratio is at 6.82. In the meantime, Its Debt-to-Equity ratio is 0.12 whereas as Long-Term Debt/Eq ratio is at 0.10.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Leerink Partners on March 17, 2025, initiated with a Market Perform rating and assigned the stock a target price of $16.
On December 10, 2024, BTIG Research started tracking the stock assigning a Buy rating and target price of $35.
On December 06, 2024, BMO Capital Markets started tracking the stock assigning a Outperform rating and target price of $35.BMO Capital Markets initiated its Outperform rating on December 06, 2024, with a $35 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 01 ’25 when van Houte Hans sold 5,402 shares for $11.03 per share. The transaction valued at 59,598 led to the insider holds 35,512 shares of the business.
JOHANNES VAN HOUTE bought 5,402 shares of NRIX for $60,827 on Aug 01 ’25. On Jul 30 ’25, another insider, van Houte Hans, who serves as the Chief Financial Officer of the company, sold 4,304 shares for $12.01 each. As a result, the insider received 51,695 and left with 40,914 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NRIX now has a Market Capitalization of 636823104 and an Enterprise Value of 202973120. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.21 while its Price-to-Book (P/B) ratio in mrq is 1.42. Its current Enterprise Value per Revenue stands at 2.297 whereas that against EBITDA is -0.913.
Stock Price History:
The Beta on a monthly basis for NRIX is 2.34, which has changed by -0.6386117 over the last 52 weeks, in comparison to a change of 0.15101504 over the same period for the S&P500. Over the past 52 weeks, NRIX has reached a high of $29.56, while it has fallen to a 52-week low of $8.18. The 50-Day Moving Average of the stock is -16.73%, while the 200-Day Moving Average is calculated to be -37.25%.
Shares Statistics:
Over the past 3-months, NRIX traded about 892.46K shares per day on average, while over the past 10 days, NRIX traded about 1213340 shares per day. A total of 76.43M shares are outstanding, with a floating share count of 74.92M. Insiders hold about 1.99% of the company’s shares, while institutions hold 115.92% stake in the company. Shares short for NRIX as of 1757894400 were 13045894 with a Short Ratio of 14.62, compared to 1755216000 on 12876254. Therefore, it implies a Short% of Shares Outstanding of 13045894 and a Short% of Float of 20.05.
Earnings Estimates
Nurix Therapeutics Inc (NRIX) is currently under the scrutiny of 15.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is -$0.89, with high estimates of -$0.76 and low estimates of -$1.01.
Analysts are recommending an EPS of between -$2.72 and -$3.24 for the fiscal current year, implying an average EPS of -$2.96. EPS for the following year is -$3.65, with 15.0 analysts recommending between -$1.97 and -$4.51.
Revenue Estimates
A total of 17 analysts have provided revenue estimates for NRIX’s current fiscal year. The highest revenue estimate was $112.96M, while the lowest revenue estimate was $59.97M, resulting in an average revenue estimate of $91.75M. In the same quarter a year ago, actual revenue was $54.55M
